TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07453004: A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Punarlimab in Subjects With Acute G

Sponsor: TJ Biopharma Co., Ltd. · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 170 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,314,000

Rescue Site Savings

+$4,830,000

Unlock Full NCT07453004 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07453004 Rescue Dossier →